Clinical trial NCT02802943: iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL
Official title: iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Leukemia, Chronic Lymphatic
Keywords: CLL, Peptid Vaccination
Lead sponsor: University Hospital Tuebingen
Sponsor class: OTHER
Collaborators: name: Robert Bosch Gesellschaft für Medizinische Forschung mbH
name: Klinikum Stuttgart
name: Marienhospital Stuttgart
name: Katharinenhospital Stuttgart
First posted: 2016-06-16
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: MRD-negative (MRD-) patients (flow cytometry based, CLL cells in peripheral blood and bone marrow \<10-4 6-10 weeks after the end of first line treatment).

MRD-positive (MRD+) patients (flow cytometry based, CLL cells in peripheral blood or bone marrow ≥ 10-4 6-10 weeks after the end of first line treatment)
Primary purpose: TREATMENT

Brief summary: The aim of this study is to induce a peptide-specific immune response in CLL patients by multi-peptide vaccination with a patient-individualized peptide cocktail.

Detailed description: Study Duration and Schedule:

The duration of the trial for each subject is expected to be 24 months. The duration for each individual patient includes about 6 months first-line therapy according to treating physicians choice with HLA ligandome analyses of CLL cells and selection of patient-individual multipeptide vaccine being performed in parallel, 12 months study treatment and 6 months followup time. The overall duration of the trial is expected to be approximately 4 years. Recruitment of subjects will start in 09/2016. The actual overall duration or recruitment may vary.

General Criteria for Subject Selection:

For the screening procedures of this study, physically fit subjects (as defined by ECOG score ≤2) with a confirmed diagnosis of a CLL/SLL according to the IWCLL guidelines requiring treatment are eligible. First line treatment will be performed according to treating physicians choice. The trial population will consist of both genders. Gender distribution in the trial is supposed to reflect the distribution in the real patient's population (approx. 60% male and 40% female patients), i.e. there will be no prior defined quantitative ratio between females and males. To assure that the included patients have the ability to mount an immune response, immune response to an HLA matched EBV/CMV peptide mix will be assessed in the screening phase. 60ml blood will be taken at the screening study visit. Peripheral mononuclear cells will be isolated and analyzed in a 12 day IFNγ ELISPOT for memory Tcell response to an EBV/CMV peptide mix. Only patients showing a positive immune response (section 8.1.1) will be eligible to receive the study drugs after first line treatment.

For the study treatment, physically fit subjects (as defined by ECOG score ≤2) with a confirmed diagnosis of CLL according to the IWCLL guidelines, which were treated with a first line therapy according to physicians choice are eligible. Subjects must have achieved at least a PR (IWCLL guidelines for the diagnosis and treatment of CLL) after treatment with first line therapy.The end of study is determined as the date of the last visit of the last patient (LSO 04/2020).

Study Design:

Interventional, open-label, multi-center phase II trial with use of a patient-individualized multipeptide vaccine and imiquimod as adjuvant

Blinding:

No blinding will be performed to avoid unnecessary complications of intradermal injections with sodium acid solution. Method against bias in patient selection: The patient selection will be documented. Reasons for refusal will be assessed.Method against bias in treatment manualized treatment protocol, monitoring and treatment reports. Method against bias in data analysis: Monitoring, analysis by intention to treat; independent statistician.

Chronic lymphatic leukaemia-peptide vaccine (CLL-VAC) drug product (DP):

Each patient enrolled in the iVAC-CLL01 trial will receive a CLL-VAC DP specifically tailored to the individual HLA ligandome of his/her respective CLL cells. The DPs are composed of peptides that are first manufactured as drug substances. A process named CLL-VAC_v1 enables the selection of drug substances to compose the unique, patient individual CLL-VAC DPs. CLL-VAC DPs will be composed based on a peptide warehouse consisting of 40 individual peptides (drug substances; 30 HLA class I peptides (5 A\*01, 5 A\*02, 5 A\*03, 5 A\*24, 5 B\*07, 5 B\*08) and 4 HLA class II peptides. All HLA class I peptides and HLA class II peptides are shown to be immunogenic. For each patient 5 HLA class I peptides are selected from the warehouse based on patient individual HLA ligandome analysis of CLL cells and are subsequently formulated into the personalized drug; the 4 HLA class II peptides will be included in each peptide vaccine cocktail.

All warehouse peptides are manufactured by BCN PEPTIDES, S.A, Els Vinyets-Els Fogars II, 08777 Sant Quintí de Mediona (Barcelona), Spain, or by Wirkstoffpeptidlabor, University of Tübingen, Auf der Morgenstelle 15, 72076 Tübingen, Germany. Both production sites hold certificates for the production of GMP grade synthetic peptides. All peptides are synthetic peptides, which will be manufactured by well-established solid phase peptide synthesis (SPPS) procedures using Fmoc chemistry.

Aldara® (imiquimod) Cream, 5%, is supplied as in single-use packets (24 per box), each of which contains 250 mg of the cream, equivalent to 12.5 mg of imiquimod. Aldara® (Meda GmbH) is a standard good of release.

Eligibility criteria: 1. Documented diagnosis of CLL/SLL according to IWCLL guidelines.

   For Screening phase:
   * No pretreatment of CLL/SLL
   * Ability to mount an immune response: Positive immunresponse to EBV/CMV peptide mix (analyzed in 12 day recall IFNγ ELISPOT).

   For Vaccination phase:

   • Achievement of response (at least PR according to IWCLL guidelines) after first-line therapy according to treating physicians choice.
2. HLA typing positive for HLA alleles of peptides included in the warehouse with proven immunogenicity: HLA-A\*01, A\*02, A\*03, A\*24, B\*07, B\*08.
3. Ability to understand and voluntarily sign an informed consent form.
4. Age ≥ 18 years at the time of signing the informed consent form.
5. Ability to adhere to the study visit schedule and other protocol requirements.
6. Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2.
7. Negative serological Hepatitis B and C test or negative PCR in case of positive serological test without evidence of an active infection, negative HIV test within 6 weeks prior to randomization.

Primary outcomes:
measure: Induction of peptide-specific T cell responses
timeFrame: 6 month after start of therapy
Secondary outcomes:
measure: Overall Survival
timeFrame: 6 month after start of therapy
Other outcomes:
Locations:
city: Stuttgart
country: Germany
facility: Diakonie-Klinikum Stuttagrt
state: Baden-Wuerttemberg
city: Stuttgart
country: Germany
facility: Robert-Bosch-Krankenhaus Abteilung fuer Haematologie, Onkologie und Palliativmedizin
state: Baden-Wuerttemberg
city: Tuebingen
country: Germany
facility: University Hospital Tuebingen
state: Baden-Wuerttemberg
city: Stuttgart
country: Germany
facility: Marienhospital
state: Baden-Württemberg
city: Stuttgart
country: Germany
facility: Katharinenhospital
state: BW
Study officials:
References: